ST-WARD

SAFETY DATA SHEET

1. Identification

Product identifier Oxcarbazepine Oral Suspension USP, 300mg/5ml

Other means of identification Non

Recommended use Indicated in the treatment of partial seizures

Recommended restrictions None known.

Manufacturer/Importer/Supplier/Distributor information

Company name K YgH K UfX D\Ufa UWi h\Wig 7cfdcfUh\cb

Address 1809 Wilson Road

Columbus, Ohio 43228

Telephone (614) 276-4000 **Emergency phone number** (614) 276-4000

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Not classified.

OSHA defined hazards Not classified.

Label elements

Hazard symbol None.

Signal word Warning

Hazard statement This is a pharmaceutical product designed to be prescribed by a licensed health care

professional. Should any person while using this product observe any adverse health effects, they

should seek medical treatment.

Precautionary statement

Prevention Observe good industrial hygiene practices.

Response Wash hands after handling. **Storage** Store at 20 – 25 °C (68 - 77°F).

Disposal Incineration of waste at an approved USEPA incinerator is recommended.

Hazard(s) not otherwise

classified (HNOC)

None known.

3. Composition/information on ingredients

Substances

| Chemical name | Common name and synonyms | CAS number | % |
|---------------|--------------------------|------------|-----------|
| Oxcarbazepine | | 28721-07-5 | 300mg/5mL |

Composition comments Refer to Physician's Desk Reference for common components present at <1%

4. First-aid measures

Inhalation Get medical attention if symptoms occur.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical attention if symptoms occur. If ingestion of a large amount does occur,

call a poison control center immediately.

Most important

symptoms/effects, acute and

delayed

The most commonly observed adverse experiences were: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, abnormal

gait, infections and infestations.

Oxcarbazepine Oral Suspension USP, 300mg/5ml 926318 Version #: 01 Revision date: - Issue date: 25-April-2015

Indication of immediate medical attention and special treatment needed

General information

No specific antidote known. Provide general supportive measures and treat symptomatically.

Ensure that medical personnel are aware of the material(s) involved, and take precautions to

protect themselves.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Use water spray to cool unopened containers.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

General fire hazards No unusual fire or explosion hazards noted.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

Keep unnecessary personnel away. Wear appropriate personal protective equipment (See Section

Methods and materials for containment and cleaning up Wipe up with absorbent material. Following product recovery, flush area with water. Incineration of

waste at an approved USEPA incinerator is recommended.

Environmental precautions Avoid discharge into drains, water courses or onto the ground.

7. Handling and storage

Precautions for safe handling

Avoid contact with eyes, skin, and clothing. Wash hands thoroughly after handling.

Conditions for safe storage, including any incompatibilities Store at 20 – 25 °C (68 - 77°F). Use within 7 weeks of first opening bottle. Store away from

incompatible materials (see Section 10 of the SDS).

8. Exposure controls/personal protection

Occupational exposure limits

No exposure limits noted for ingredient(s).

Biological limit values

No biological exposure limits noted for the ingredient(s).

Appropriate engineering

controls

Ventilation should be matched to conditions.

Individual protection measures, such as personal protective equipment

Eye/face protection

None required for consumer use. In laboratory, medical or industrial settings, safety glasses with side shields are recommended. The use of goggles or full face protection may be required depending on the industrial exposure setting. Contact a health and safety professional for specific information.

Skin protection

Hand protection

For consumer use, no unusual precautions are necessary.

Other

None required for consumer use. In laboratory, medical or industrial settings, gloves and lab coats are recommended. The use of additional personal protective equipment such as shoe coverings, gauntlets, hood or head coverings may be necessary. Contact a health and safety professional for

specific information.

Respiratory protection

None required for consumer use. Respirators may be required for certain laboratory and manufacturing tasks if engineering controls do not maintain airborne concentrations below recommended exposure limits (where applicable) or to an acceptable level (where exposure limits have not been established). Workplace risk assessments should be completed before specifying and implementing respirator usage. All respirators must conform to specifications for efficiency and performance. In the United States of America, if respirators are used, a program should be instituted to assure compliance with OSHA Standard 29 CFR 1910.134. Respirator type: Air-purifying respirator with an appropriate, air-purifying filter, cartridge or canister. Contact a

health and safety professional or manufacturer for specific information.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

SDS US

General hygiene considerations

Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Appearance

Physical state Liquid. Form Liquid.

Color Off-white to slightly brown or red.

Odor Not available.
Odor threshold Not available.
pH Not available.
Melting point/freezing point Not available.
Initial boiling point and boiling Not available.

range

Flash point Not available.

Evaporation rate Not available.

Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

(%)

Explosive limit - lower (%) Not available.

Explosive limit - upper (%) Not available.

Vapor pressure Not available.

Vapor density Not available.

Relative density Not available.

Solubility(ies)

Solubility (water) Insoluble

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available.

Decomposition temperature Not available.

Viscosity Not available.

10. Stability and reactivity

ReactivityThe product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoidContact with incompatible materials. Exposure to light.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on likely routes of exposure

InhalationNot expected to be hazardous in final pharmaceutical form.Skin contactNot expected to be hazardous in final pharmaceutical form.

Eye contact Not expected to be hazardous in final pharmaceutical form. Contact with eyes may cause

temporary irritation.

Ingestion Ingestion may cause irritation and stomach discomfort.

Oxcarbazepine Oral Suspension USP, 300mg/5ml 926318 Version #: 01 Revision date: - Issue date: 25-April-2015 Symptoms related to the physical, chemical and toxicological characteristics

The most commonly observed adverse experiences were: dizziness, somnolence, diplopia, fatigue, nausea, vomiting, ataxia, abnormal vision, abdominal pain, tremor, dyspepsia, abnormal

gait, infections and infestations.

Information on toxicological effects

Acute toxicity May be harmful if swallowed in large quantities.

Skin corrosion/irritation Prolonged skin contact may cause temporary irritation.

Serious eye damage/eye

irritation

May cause temporary eye irritation.

Respiratory or skin sensitization

Respiratory sensitization Not a respiratory sensitizer.

Skin sensitization Not expected to be a skin sensitizer.

Germ cell mutagenicity Positive in vitro, but negative in vivo assays.

Carcinogenicity Mice and rats were administered high doses in a 2 year carcinogenicity study. Hepatocellular

adenomas, hepatocellar carcinomas and tumors of the cervix, vagina, and testicular interstital

cells were observed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

Reproductive toxicity Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women.

Drug is present in breast milk. A decision should be made whether to discontinue the drug, taking

into account the importance of the drug to the mother.

Specific target organ toxicity -

single exposure

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Aspiration hazard Not classified.

Further information See package insert.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous.

Persistence and degradability N

No data is available on the degradability of this product.

Bioaccumulative potential

No data available.

Mobility in soil

Expected to be mobile in soil.

Other adverse effects None.

13. Disposal considerations

Disposal instructionsCollect and reclaim or dispose in sealed containers at licensed waste disposal site.

Local disposal regulations

Dispose in accordance with all applicable regulations.

Hazardous waste code

The waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Contaminated packaging

Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Not a

Annex II of MARPOL 73/78 and

Not applicable.

the IBC Code

15. Regulatory information

US federal regulations

This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use.

Over-the-counter drugs in their solid final form (i.e. tablets or pills) are considered exempt under the criteria of the Federal OSHA Hazard Communication Standard 29 CFR 1910.1200. However, in an industrial setting where a component's occupational exposure limits may be surpassed, they can be considered hazardous.

OSHA GHS: GHS symbols in consumer packaged form are not required per OSHA 29 CFR 1910.1200(b)(5) and OSHA 29 CFR 1910.1200(b)(5)(iii).

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not listed.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - No

Delayed Hazard - No Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act Not regulated.

(SDWA)

US state regulations

US. Massachusetts RTK - Substance List

Not regulated.

US. New Jersey Worker and Community Right-to-Know Act

Not listed

US. Pennsylvania Worker and Community Right-to-Know Law

Not listed.

US. Rhode Island RTK

Not regulated.

US. California Proposition 65

California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

| Country(s) or region | Inventory name | On inventory (yes/no)* |
|----------------------|--|------------------------|
| Australia | Australian Inventory of Chemical Substances (AICS) | No |
| Canada | Domestic Substances List (DSL) | No |
| Canada | Non-Domestic Substances List (NDSL) | No |
| China | Inventory of Existing Chemical Substances in China (IECSC) | No |
| Europe | European Inventory of Existing Commercial Chemical Substances (EINECS) | Yes |

| Country(s) or region | Inventory name | On inventory (yes/no)* |
|----------------------|---|------------------------|
| Europe | European List of Notified Chemical Substances (ELINCS) | No |
| Japan | Inventory of Existing and New Chemical Substances (ENCS) | No |
| Korea | Existing Chemicals List (ECL) | No |
| New Zealand | New Zealand Inventory | No |
| Philippines | Philippine Inventory of Chemicals and Chemical Substances (PICCS) | No |

^{*}A "Yes" indicates this product complies with the inventory requirements administered by the governing country(s).

Toxic Substances Control Act (TSCA) Inventory

16. Other information, including date of preparation or last revision

Issue date 25-April-2015

Revision date - 01

United States & Puerto Rico

References 1) Oxcarbazepine Oral Suspension USP, 300mg/5mL, Package Insert, West-Ward Pharmaceuticals

Corporation, Columbus, Ohio

2) PDR – Physicians Desk Reference.

3) Ariel Webinsight. Regulatory and ChemExpert Database.

Disclaimer West-Ward Pharmaceuticals Corporation cannot anticipate all conditions under which this information and

its product, or the products of other manufacturers in combination with its product, may be used. It is the user's responsibility to ensure safe conditions for handling, storage and disposal of the product, and to assume liability for loss, injury, damage or expense due to improper use. The information in the sheet was written based on the best knowledge and experience currently

available.

Oxcarbazepine Oral Suspension USP, 300mg/5ml

926318 Version #: 01 Revision date: - Issue date: 25-April-2015 6 / 6

No

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).